Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

45720

Sigma-Aldrich

Eserine salicylate salt

≥97.0% (N)

Sinónimos:

Physostigmine salicylate salt

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C15H21N3O2 · C7H6O3
Número de CAS:
57-64-7
Peso molecular:
413.47
Beilstein/REAXYS Number:
3900576
EC Number:
200-343-8
MDL number:
MFCD00135659
UNSPSC Code:
12352005
PubChem Substance ID:
57650461

biological source

synthetic

assay

≥97.0% (N)

form

powder

optical activity

[α]20/D −77±2°, c = 1% in ethanol

mp

181-183 °C

SMILES string

OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2

InChI

1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1

InChI key

HZOTZTANVBDFOF-PBCQUBLHSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Acetylcholinesterase inhibitor that crosses the blood-brain barrier and forms a carbamylated enzyme complex with acetyl cholinesterase that degrades slowly.

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
BCBF9932V
1056576V
1056576
416955/1
376717/1

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

F Matschiner et al.
HNO, 49(12), 1026-1028 (2002-01-17)
Appearance of an anticholinergic syndrome after treatment with drugs in therapeutic dosages is seldom reported in the literature. Based on a case report, the development and course of an anticholinergic syndrome after treatment with dimenhydrinate are described. The drug was
F J Forno et al.
The Journal of the American Osteopathic Association, 98(9), 502-504 (1998-10-24)
Ingestion of jimsonweed can result in hallucinations. Despite this side effect, the differential diagnosis of jimsonweed toxicity can be difficult, in part, because routine drug screens do not detect this agent. Such a delay in diagnosis not only postpones treatment
Noushin Bolourchian et al.
Acta pharmaceutica (Zagreb, Croatia), 59(3), 301-312 (2009-10-13)
This study is aimed to design and optimize a sublingual tablet formulation of physostigmine salicylate, an effective drug in Alzheimer's disease and nerve gas poisoning, by means of the D-optimal experimental design methodology. Polyvinyl pyrrolidone, lactose, starch 1500 and sodium
H Jesionowska et al.
The Journal of reproductive medicine, 36(3), 167-169 (1991-03-01)
A subcutaneous injection of physostigmine was employed to treat paraplegic anejaculation. The sperm motility was greater than in previously reported studies in which electroejaculation techniques were used for seminal emission.
A Bringmann
Neuroscience letters, 202(1-2), 13-16 (1995-12-29)
In previous experiments it was found that physostigmine application in unrestrained rats delayed the peak latency of the visual evoked potential (VEP). The present study was carried out to find the putative site that cholinergically mediates the latency delay of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico